Estrogen therapy and coronary-artery calcification. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML, WHI and WHI-CACS Investigators (2007) N Engl J Med 356: 2591-602 Breast cancer and hormone-replacement therapy. Dupont WD (1995) N Engl J Med 333: 1356-7; author reply 1357-8 A three-part intervention to change the use of hormone replacement therapy in response to new evidence. Roumie CL, Grogan EL, Falbe W, Awad J, Speroff T, Dittus RS, Elasy TA (2004) Ann Intern Med 141: 118-25 The effects of hormone replacement therapy on hypothalamic neuropeptide gene expression in a primate model of menopause. Abel TW, Voytko ML, Rance NE (1999) J Clin Endocrinol Metab 84: 2111-8 Estrogen replacement therapy in women with a history of proliferative breast disease. Dupont WD, Page DL, Parl FF, Plummer WD, Schuyler PA, Kasami M, Jensen RA (1999) Cancer 85: 1277-83 Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Xu WH, Shu XO, Long J, Lu W, Cai Q, Zheng Y, Xiang YB, Dai Q, Zhao GM, Gu K, Bao PP, Gao YT, Zheng W (2011) Am J Epidemiol 173: 923-31 Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study. Qu S, Wen W, Shu XO, Chow WH, Xiang YB, Wu J, Ji BT, Rothman N, Yang G, Cai Q, Gao YT, Zheng W (2013) Am J Epidemiol 177: 617-24 Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS (2012) Cancer Epidemiol Biomarkers Prev 21: 20-38 Estrogen-cholinergic interactions: Implications for cognitive aging. Newhouse P, Dumas J (2015) Horm Behav 74: 173-85 Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Vajo Z, Terry JG, Brinton EA (2002) Atherosclerosis 160: 495-501 Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome. Romero-Aleshire MJ, Diamond-Stanic MK, Hasty AH, Hoyer PB, Brooks HL (2009) Am J Physiol Regul Integr Comp Physiol 297: R587-92 Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study. Bowden DW, Lohman K, Hsu FC, Langefeld CD, Carr JJ, Lenchik L, Wagenknecht LE, Freedman BI, Herrington DM (2006) Diabet Med 23: 763-7 Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, Phillips L, Cochrane BB, Eaton CB, Greenland P, Hendrix S, Hsia J, Hunt JR, Jackson RD, Johnson KC, Kuller LH, Robinson J, Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators (2008) Menopause 15: 639-47 Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Andersen SW, Trentham-Dietz A, Figueroa JD, Titus LJ, Cai Q, Long J, Hampton JM, Egan KM, Newcomb PA (2013) Menopause 20: 354-8 Reproductive and hormonal factors and pancreatic cancer risk in women. Lucenteforte E, Zucchetto A, Bosetti C, Talamini R, Negri E, Serraino D, Franceschi S, Lipworth L, La Vecchia C (2011) Pancreas 40: 460-3 Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS (2009) Ann Epidemiol 19: 1-7 Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment? Laster AJ, Tanner SB (2011) Rheum Dis Clin North Am 37: 323-36, v
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.